Skip to main content
    L

    Legend Biotech Corp (LEGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.99
    -1.51 (-8.63%)

    Market Cap: $3.39B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Legend Biotech Corp (LEGN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Legend Biotech reported revenue of $1.03B for the fiscal year ended Dec 31, 2025, up 64.0% from the year before. That year, net income was -$296.80M with a net margin of -28.8%, operating cash flow was -$100.47M and free cash flow was -$168.04M. The quarter ended Sep 30, 2026 had revenue of $359.50M and net income of $51.70M.

    Revenue and Margins

    The operating margin was -13.3% in the fiscal year ended Dec 2025. Over the 8 years to Dec 2025, revenue grew from $23.59M, a compound annual rate of 60.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.03B+64.0%60.3%-13.3%-28.8%
    Dec 2024$627.24M+120.0%62.6%-48.3%-28.2%
    Dec 2023$285.14M+143.7%49.4%-154.1%-181.8%
    Dec 2022$117.00M+70.0%44.1%-389.4%-381.5%
    Dec 2021$68.83M-8.2%100.0%-570.0%-586.4%
    Dec 2020$75.00M+21.4%100.0%-417.8%-355.2%
    Dec 2019$61.80M+25.8%100.0%-214.4%-164.4%
    Dec 2018$49.13M+108.2%100.0%-3.1%-5.7%
    Dec 2017$23.59MN/A100.4%58.4%39.7%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$1.03B$627.24M$285.14M$117.00M$68.83M$75.00M$61.80M$49.13M$23.59M
    Cost of revenue$408.10M$234.58M$144.21M$65.36M$313.35M$232.16MN/AN/A-$96.00K
    Gross profit$620.80M$392.66M$140.93M$51.64M$68.83M$75.00M$61.80M$49.13M$23.69M
    Research and development$414.70M$413.54M$382.22M$335.65M$313.35M$232.16M$161.94M$60.64M$8.20M
    Operating income-$136.50M-$303.24M-$439.49M-$455.62M-$392.29M-$313.35M-$132.51M-$1.53M$13.78M
    Net income-$296.80M-$177.03M-$518.25M-$446.35M-$403.58M-$266.37M-$101.59M-$2.78M$9.37M
    EBITDAN/A-$113.16MN/A-$416.54MN/A-$298.16M-$127.25M$149.00K$14.06M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$359.50M$387.50M$305.10M$306.38M$272.33M$255.06M$195.05M$186.52M$160.21M$186.52M$93.99M$79.46M
    Gross profit$211.90M$250.10M$129.20M$182.92M$157.02M$157.07M$123.71M$112.60M$104.74M$136.07M$39.25M$47.01M
    Operating income$46.80M$57.70M-$49.80M-$20.60M-$43.45M-$21.88M-$50.65M-$74.39M-$70.05M-$41.97M-$117.86M-$119.85M
    Net income$51.70M$33.20M-$54.30M-$30.82M-$39.69M-$125.38M-$100.92M$26.28M-$125.32M-$18.20M-$59.79M-$144.82M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $326.50M by $575.40M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$1.73B$1.67B$1.85B$1.33B$1.12B$722.09M$287.71M$429.05M$238.69M
    Current assets$1.25B$1.28B$1.50B$1.10B$949.85M$593.94M$207.10M$326.96M$230.90M
    Cash and equivalents$901.90M$286.75M$1.28B$786.03M$688.94M$456.07M$83.36M$210.17M$2.12M
    Total liabilities$731.60M$629.61M$597.24M$586.65M$353.52M$122.27M$410.58M$420.40M$226.53M
    Short-term debt$326.50M$4.79M$3.17M$3.56M$911.00K$1.79M$1.03M$373.00K$64.00K
    Long-term debtN/A$301.20M$281.33M$260.93M$120.46MN/AN/AN/AN/A
    Shareholder equity$1.00B$1.04B$1.25B$744.31M$765.94M$597.77M-$122.87M$8.65M$12.17M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.68B$1.75B$1.60B$1.73B$1.71B$1.69B$1.62B$1.67B$1.74B$1.80B$1.78B$1.85B
    Total liabilities$408.70M$521.32M$629.02M$731.60M$701.69M$654.38M$597.90M$629.61M$619.72M$639.18M$611.05M$597.24M
    Cash and equivalents$460.70M$672.92M$646.42M$901.90M$278.89M$266.59M$441.70M$286.75M$459.28M$201.25M$897.57M$1.28B
    Shareholder equity$1.27B$1.23B$967.73M$1.00B$1.01B$1.04B$1.02B$1.04B$1.12B$1.16B$1.16B$1.25B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$100.47M-$144.03M-$393.28M-$201.28M-$198.47M-$223.00M-$83.06M$307.68M-$2.38M
    Capital expenditures$67.58M$14.11M$22.72M$22.27M$45.40M$30.28M$39.17M$21.02M$887.00K
    Free cash flow-$168.04M-$158.14M-$416.00M-$223.56M-$243.87M-$253.29M-$122.23M$286.66M-$3.26M
    Investing cash flow$711.48M-$850.54M$92.79M-$77.09M-$194.98M-$24.17M-$58.65M-$102.26M-$827.00K
    Financing cash flow-$300.79K$5.70M$791.49M$377.98M$626.66M$618.88M$14.67M$2.50M$3.32M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$35.90M-$20.90M-$85.35M-$105.64M$28.80M-$13.04M-$103.75M-$82.08M-$75.82M-$1.65M$15.52M-$95.64M
    Capital expenditures$5.60M$20.62M$25.98M$20.92M$5.00M$9.22M$2.00M$2.38M$2.06M$3.42M$6.25M$6.85M
    Free cash flow-$41.50M-$41.52M-$111.33M-$126.56M$23.80M-$22.27M-$105.76M-$84.46M-$77.89M-$5.07M$9.27M-$102.49M
    Last 12 quarters

    Frequently Asked Questions About LEGN

    What is Legend Biotech's annual revenue?

    Legend Biotech reported revenue of $1.03B for the fiscal year ended Dec 31, 2025.

    How fast is Legend Biotech's revenue growing?

    Revenue was up 64.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 106.4%.

    Is Legend Biotech profitable?

    No. Legend Biotech reported net income of -$296.80M for the fiscal year ended Dec 31, 2025, with a net margin of -28.8%.

    How much free cash flow does LEGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$100.47M minus capital expenditures of $67.58M produced free cash flow of -$168.04M.

    How much debt does Legend Biotech have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $326.50M and cash and equivalents of $901.90M.